-去背.png){kind=logo}
News
-
artiCure and TFBS Bioscience Join Forces in Virus Manufacturing to Advance Development of Innovative Cancer Gene Therapy
2025-08-28 artiCure and TFBS Bioscience Join Forces in Virus Manufacturing to Advance Development of Innovative Cancer Gene Therapy Korea’s innovative cancer therapy company artiCure and leading viral vector manufacturer from Taiwan, TFBS Bioscience Inc. jointly announce the collaboration on GMP manufacturing of retroviral vectors, aiming to accelerate clinical trials of cancer gene therapy in Korea. Learn more -
TFBS Bioscience and U-Medico Announce Strategic Alliance to Launch GMP QC Testing Services for CGT therapeutics
2025-08-28 TFBS Bioscience and U-Medico Announce Strategic Alliance to Launch GMP QC Testing Services for CGT therapeutics TFBS Bioscience Inc., a Taiwan and Japan-based company offering total solutions for GMP manufacturing of viral vector and U-Medico Inc., a leading Japanese company providing advanced analytical solutions, today announced a strategic partnership to jointly launch a new suite of Good Manufacturing Practice (GMP) Quality Control (QC) testing services. This collaboration marks a significant milestone in international cooperation, aiming at delivering accurate, regulatory-compliant QC testing services for viral vectors across Japan, Taiwan, and the broader Asia-Pacific region. Learn more -
AAVnerGene and TFBS Bioscience Announce Collaboration to Develop Innovative AAV Vector Technology Platform for Gene Therapy
2025-07-16 AAVnerGene and TFBS Bioscience Announce Collaboration to Develop Innovative AAV Vector Technology Platform for Gene Therapy AAVnerGene Inc. and TFBS Bioscience Inc. today announced a collaboration on the development and application of innovative adeno-associated virus (AAV) vector technologies for manufacturing, including key areas such as AAV tropism enhancement and manufacturing process optimization. Learn more -
Taiwan’s Gene Therapy Pioneer Dr. Wuh-Liang Hwu Partners with TFBS Bioscience to Advance Gene Therapy for Rare Disease
2025-06-11 Taiwan’s Gene Therapy Pioneer Dr. Wuh-Liang Hwu Partners with TFBS Bioscience to Advance Gene Therapy for Rare Disease Dr. Paul Wuh-Liang Hwu, MD, PhD, Professor Emeritus of Pediatrics and Medical Genetics at National Taiwan University, and Distinguished Research Fellow at the Center for Precision Medicine, China Medical University Hospital, has recently launched a new gene therapy development project targeting Sialidosis, a rare genetic disorder. The research utilizes adeno-associated virus serotype 9 (AAV9) as a vector to deliver the sialidase gene into the human body, offering a potential effective treatment for patients. TFBS Bioscience, serving as the manufacturing partner, will provide a one-stop service for AAV9 vector process development, GMP-grade clinical trial material manufacturing, and quality and safety testing to support Phase I/II clinical trials. Learn more
